“Whether or not” and “how” to taper off the last bit of medication for patients with clinically stable ANCA-associated vasculitis are hotly debated topics in the vasculitis field.
This is a study of 30 patients with immune checkpoint inhibitor induced inflammatory arthritis. Their clinical features and relationship to immunotherapy regimen were evaluated, as was the course of their arthritis.
A new study from the Johns Hopkins Arthritis Center reveals that cigarette smoking is not linked to the development of antibodies to PAD4 in patients with severe rheumatoid arthritis.
An antibody biomarker was recently discovered that identifies people with chronic skeletal muscle disease and severe heart muscle involvement.
A survey of more than 600 people with myositis from the US, Korea, and Sweden identified 5 aspects of living with the disease that are most important to patients.
A new study found that people with scleroderma who have muscle weakness due to the accumulation of fibrous tissue in their muscles, are at risk for severe disease outcomes including death from heart disease.
A collaborative effort between Rheumatology and Oncology offers guidance to doctors treating patients for inflammatory arthritis caused by treatment with “immune checkpoint inhibitors”, a type of cancer therapy.
A study lead by Lisa Christopher-Stine, M.D., M.P.H. identified “Hiker’s Feet” as a new skin finding in some patients with inflammatory muscle disease (myositis).
Younger patients with a specific form of myositis associated with antibodies to a protein called HMGCR have a worse prognosis than older patients.